Showing results (161-170 of 237) with videos related to

Sort By:
Pageof 24
Journal of Nippon Medical School = Nippon Ika Daigaku Zasshi|November 29, 2019
Exosome-Derived microRNA-22 Ameliorates Pulmonary Fibrosis by Regulating Fibroblast-to-Myofibroblast Differentiation in Vitro and in VivoNaoyuki Kuse, Koichiro Kamio, Arata Azuma, et al.
BMC Cancer|April 18, 2015
MET FISH-positive status predicts short progression-free survival and overall survival after gefitinib treatment in lung adenocarcinoma with EGFR mutationRintaro Noro, Masahiro Seike, Fenfei Zou, et al.
Oncotargets and Therapy|June 14, 2022
Successful Treatment with Short-Term Steroid Against Severe Hepatitis Confirmed by Liver Biopsy in a Patient with Advanced Squamous-Cell Lung Cancer Receiving a Combination of Pembrolizumab, Carboplatin, and Nab-Paclitaxel: A Case ReportAnna Hayashi, Shinji Nakamichi, Yukako Nakayama, et al.
Anticancer Research|April 4, 2021
Impact of Renin-angiotensin System Inhibitors on the Efficacy of Anti-PD-1/PD-L1 Antibodies in NSCLC PatientsTakehiro Tozuka, Noriko Yanagitani, Hiroshi Yoshida, et al.
Cancer Chemotherapy and Pharmacology|November 27, 2012
Bevacizumab plus chemotherapy for advanced non-squamous non-small-cell lung cancer with malignant pleural effusionKazuhiro Kitamura, Kaoru Kubota, Masahiro Ando, et al.
Cancer Treatment and Research Communications|November 29, 2020
Association between continuous decrease of plasma VEGF-A levels and the efficacy of chemotherapy in combination with anti-programmed cell death 1 antibody in non-small cell lung cancer patientsTakehiro Tozuka, Noriko Yanagitani, Hiroaki Sakamoto, et al.
Respiratory Investigation|May 15, 2026
Pulmonary vascular resistance is associated with two-year clinical outcomes in non-hypoxemic COPD with mild pulmonary hemodynamic abnormalitiesShun Idei, Yosuke Tanaka, Fushi Dong, et al.
Journal for Immunotherapy of Cancer|March 1, 2019
Intralymphatic histiocytosis in a patient with lung adenocarcinoma treated with pembrolizumab: a case reportTeppei Sugano, Masahiro Seike, Yoko Funasaka, et al.
Investigational New Drugs|April 14, 2023
Soluble interleukin-2 receptor as a predictive biomarker for poor efficacy of combination treatment with anti-PD-1/PD-L1 antibodies and chemotherapy in non-small cell lung cancer patientsTakehiro Tozuka, Noriko Yanagitani, Hiroshi Yoshida, et al.
Oncotargets and Therapy|June 29, 2023
Remarkable Clinical Response of ALK-Rearranged/TP53-Mutant Lung Adenocarcinoma with Liver Metastasis to Atezolizumab-Bevacizumab-Carboplatin-Paclitaxel After ALK Inhibitors: A Case ReportHirokazu Iso, Akihiko Miyanaga, Naohiro Kadoma, et al.
Pageof 24